[go: up one dir, main page]

EP0383129A3 - Pancreatic islet cell antigens obtained by molecular cloning - Google Patents

Pancreatic islet cell antigens obtained by molecular cloning Download PDF

Info

Publication number
EP0383129A3
EP0383129A3 EP19900102179 EP90102179A EP0383129A3 EP 0383129 A3 EP0383129 A3 EP 0383129A3 EP 19900102179 EP19900102179 EP 19900102179 EP 90102179 A EP90102179 A EP 90102179A EP 0383129 A3 EP0383129 A3 EP 0383129A3
Authority
EP
European Patent Office
Prior art keywords
iddm
cell antigens
pancreatic islet
islet cell
ica
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19900102179
Other languages
German (de)
French (fr)
Other versions
EP0383129A2 (en
EP0383129B1 (en
Inventor
Daniel Rabin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Molecular Diagnostics Inc
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Diagnostics Inc, Bayer Corp filed Critical Molecular Diagnostics Inc
Publication of EP0383129A2 publication Critical patent/EP0383129A2/en
Publication of EP0383129A3 publication Critical patent/EP0383129A3/en
Application granted granted Critical
Publication of EP0383129B1 publication Critical patent/EP0383129B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Pancreatic islet cell antigens (ICA) that bind with antibodies found in the sera of patients afflicted with insulin-dependent (Type I) diabetes mellitus (IDDM). ICA proteins are expressed by recombinant cloning vehicles comprising DNA inserts isolated from islet cells. Full sequence native ICA proteins, or protein or peptide fragments thereof, can be used in the diagnosis of IDDM and in detecting or blocking human immunoglobulin, T-cells, or B-cells involved in IDDM.
EP90102179A 1989-02-17 1990-02-03 Pancreatic islet cell antigens obtained by molecular cloning Expired - Lifetime EP0383129B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31254389A 1989-02-17 1989-02-17
US312543 1989-02-17
US44170389A 1989-12-04 1989-12-04
US441703 1989-12-04

Publications (3)

Publication Number Publication Date
EP0383129A2 EP0383129A2 (en) 1990-08-22
EP0383129A3 true EP0383129A3 (en) 1991-07-31
EP0383129B1 EP0383129B1 (en) 1995-05-10

Family

ID=26978437

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90102179A Expired - Lifetime EP0383129B1 (en) 1989-02-17 1990-02-03 Pancreatic islet cell antigens obtained by molecular cloning

Country Status (14)

Country Link
EP (1) EP0383129B1 (en)
JP (1) JP2858467B2 (en)
AT (1) ATE122394T1 (en)
AU (1) AU626636B2 (en)
CA (1) CA2010275C (en)
DE (1) DE69019190T2 (en)
DK (1) DK0383129T3 (en)
ES (1) ES2072928T3 (en)
FI (1) FI103730B1 (en)
GR (1) GR3017019T3 (en)
IE (1) IE66997B1 (en)
IL (1) IL93397A (en)
NO (1) NO306996B1 (en)
PT (1) PT93166B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) * 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
JPH02200700A (en) * 1989-01-30 1990-08-08 Shionogi & Co Ltd New reg protein
US5744327A (en) * 1990-02-20 1998-04-28 Board Of Regents, The University Of Texas System Methods for producing insulin in response to non-glucose secretagogues
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
US5175085A (en) * 1990-02-20 1992-12-29 Board Of Regents, The University Of Texas System Methods and compositions for diagnosing autoimmune insulin dependent diabetes mellitus
ES2223039T3 (en) 1990-09-07 2005-02-16 The Regents Of The University Of California METHODS FOR DIAGNOSIS AND TREATMENT OF DIABETES.
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5998366A (en) * 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
AU8864791A (en) * 1990-10-02 1992-04-28 Trigen Incorporated Antibodies and methods for diagnosis and treatment of diabetes
EP0585356A1 (en) * 1991-05-15 1994-03-09 Zymogenetics, Inc. Cloning and expression of human islet glutamic acid decarboxylase autoantigen
US5792656A (en) * 1991-06-03 1998-08-11 Board Of Regents, The University Of Texas System Methods of preparing genetically engineered cells that produce insulin in response to glucose
EP0627934A4 (en) * 1992-02-27 1997-01-08 Univ Leland Stanford Junior EARLY ANTIGEN FOR AUTOIMMUN DIABETES.
US5200318A (en) * 1992-05-13 1993-04-06 Miles Inc. Diagnosis of IDDM with a panel of immunoreagents
WO1996038479A1 (en) * 1995-05-30 1996-12-05 Fujisawa Pharmaceutical Co., Ltd. Method of diagnosis of insulin dependent diabetes melitus and kit to be used therein
AU1989097A (en) 1996-03-06 1997-09-22 University Of Washington Diabetes mellitus 37 kd autoantigen protein-tyrosine phosphatase
CA2288343A1 (en) * 1997-04-25 1998-11-05 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CN110244051A (en) * 2019-07-05 2019-09-17 许昌学院 A multicomponent marker immunoassay system for diabetes

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084796A2 (en) * 1982-01-22 1983-08-03 Cetus Corporation HLA typing method and cDNA probes used therein
GB2146338A (en) * 1983-09-11 1985-04-17 Yeda Res & Dev Cell membrane proteins
WO1986007464A1 (en) * 1985-06-14 1986-12-18 Genetic Systems Corporation Methods for identifying alleles associated with increased risk of diabetes
EP0286447A2 (en) * 1987-04-09 1988-10-12 The Board Of Trustees Of The Leland Stanford Junior University Method and agents relating to prophylactic treatment of autoimmune diseases
WO1988010120A1 (en) * 1987-06-24 1988-12-29 Brigham And Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084796A2 (en) * 1982-01-22 1983-08-03 Cetus Corporation HLA typing method and cDNA probes used therein
GB2146338A (en) * 1983-09-11 1985-04-17 Yeda Res & Dev Cell membrane proteins
WO1986007464A1 (en) * 1985-06-14 1986-12-18 Genetic Systems Corporation Methods for identifying alleles associated with increased risk of diabetes
EP0286447A2 (en) * 1987-04-09 1988-10-12 The Board Of Trustees Of The Leland Stanford Junior University Method and agents relating to prophylactic treatment of autoimmune diseases
WO1988010120A1 (en) * 1987-06-24 1988-12-29 Brigham And Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOSIS ACCESSION NO. 64050513 W.J. IRVINE et al.: "Pancreatic islet cell antibody as a marker for asymtomatic and latent diabetes and pre diabetes" & Lancet 1976, vol. 2, no. 7995, pages 1098-1102 *
BIOSIS ACCESSION NO. 82043197 I. MATSUBA et al.: "Studies on the pathogenesis of insulin-dependent diabetes mellitus autoantigens recognized by islet cell surface antibodies" & J. Jpn. Diabetes Soc. 1986, vol. 29, no. 3, pages 261-265 *
COMPTES RENDUS DE L'ACADEMIE DES SCIENCES - SCIENCES DE LA VIE - SERIE III vol. 309, no. 7, 1989, pages 229-234, Paris, F; C. BOITARD et al.: "Réaction croisée entre les antigènes de classe II du complexe majeur d'histocompatibilité de la souris NOD et un antigène insulaire de poids moléculaire de 58kDa" *
DIABETES METABOLISM REVIEWS vol. 3/4, 1987, pages 959-980, US; A. LERNMARK et al.: "Islet-specific immune mechanisms" *
DIABETES vol. 34, no. 6, June 1985, pages 617-619, New York, US; R.C. NAYAK et al.: "'Cytoplasmic' islet cell antibodies. Evidence that the target antigen is a sialoglycoconjugate" *
JOURNAL OF CLINICAL INVESTIGATION vol. 79, no. 3, March 1987, pages 926-934, New York, US; S. BAEKKESKOV et al.: "Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes" *
NATURE vol. 298, 8 July 1982, pages 167-169, London, GB; B. BAEKKESKOV et al.: "Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins" *
SCIENTIFIC AMERICAN July 1990, pages 42-49, New York, US; M.A. ATKINSON et al. "What causes diabetes?" *

Also Published As

Publication number Publication date
NO900474D0 (en) 1990-02-01
IE900589L (en) 1990-08-17
PT93166A (en) 1990-08-31
CA2010275A1 (en) 1990-08-17
PT93166B (en) 1997-11-28
AU4988390A (en) 1990-08-23
ATE122394T1 (en) 1995-05-15
NO306996B1 (en) 2000-01-24
FI900759A0 (en) 1990-02-15
JP2858467B2 (en) 1999-02-17
CA2010275C (en) 2000-08-29
EP0383129A2 (en) 1990-08-22
FI103730B (en) 1999-08-31
GR3017019T3 (en) 1995-11-30
DE69019190T2 (en) 1995-09-14
AU626636B2 (en) 1992-08-06
EP0383129B1 (en) 1995-05-10
ES2072928T3 (en) 1995-08-01
IL93397A0 (en) 1990-11-29
JPH0347133A (en) 1991-02-28
FI103730B1 (en) 1999-08-31
DE69019190D1 (en) 1995-06-14
IL93397A (en) 1997-06-10
IE66997B1 (en) 1996-02-21
NO900474L (en) 1990-08-20
DK0383129T3 (en) 1995-10-09

Similar Documents

Publication Publication Date Title
AU626636B2 (en) Pancreatic islet cell antigens obtained by molecular cloning
AU3192889A (en) T cell activation markers
DE3671633D1 (en) Htlv iii polypeptide.
WO2001053349A3 (en) Small cell lung cancer associated antigens and uses therefor
BR9809443A (en) Polypeptide comprising an antigenic portion of an antigen of m. tuberculosis, dna molecule, recombinant expression vector, host cell, process for detection of m. tuberculosis in a biological sample, diagnostic kit, monoclonal antibody, polyclonal antibody, and fusion protein.
DE68925226D1 (en) Monoclonal antibodies
WO2000020587A3 (en) Cancer associated antigens and uses therefor
KR100215606B1 (en) Toxoplasma gondii antigens, the preparation thereof and the diagnostic agent containing them
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
WO2000036087A3 (en) Nucleolus autoantigenic marker for systematic lupus erythematosus
EP0331356A3 (en) Expression of hiv binding proteins
HK1004949A1 (en) Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
AU630861B2 (en) Recombinant hiv-2 polypeptides
WO1995019371A3 (en) Expression of surface layer proteins
EP0293827A3 (en) Assay for leishmaniasis
EP0177814A3 (en) Peptide antibodies and their use in detecting oncogene products
WO1992007939A3 (en) Polypeptide with 46kd hmfg differentiation antigen binding specificity
WO2003097814A3 (en) Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins
WO2001000874A3 (en) Cancer associated antigens and uses therefor
KR920002631A (en) Class II protein of Neisseria meningitidis outer membrane with immunological carrier and enhancing properties
WO2000072021A3 (en) Cancer associated antigens and uses therefor
WO2000020586A3 (en) Renal cancer associated antigens and uses therefor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900209

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MILES INC.

17Q First examination report despatched

Effective date: 19930721

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 122394

Country of ref document: AT

Date of ref document: 19950515

Kind code of ref document: T

REF Corresponds to:

Ref document number: 69019190

Country of ref document: DE

Date of ref document: 19950614

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: BAYER CORPORATION

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: BAYER CORPORATION

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: MILES INC. TRANSFER- BAYER CORPORATION

ITF It: translation for a ep patent filed
RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: BAYER CORPORATION

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2072928

Country of ref document: ES

Kind code of ref document: T3

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: BAYER CORPORATION;MILES INC.

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3017019

ITPR It: changes in ownership of a european patent

Owner name: CESSIONE EPO;BAYER CORPORATION

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: BAYER CORPORATION

Free format text: BAYER CORPORATION#ONE MELLON CENTER 500 GRANT ST.#PITTSBURGH/PA (US) -TRANSFER TO- BAYER CORPORATION#ONE MELLON CENTER 500 GRANT ST.#PITTSBURGH/PA (US)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20090212

Year of fee payment: 20

Ref country code: AT

Payment date: 20090115

Year of fee payment: 20

Ref country code: LU

Payment date: 20090217

Year of fee payment: 20

Ref country code: ES

Payment date: 20090313

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20090213

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20090216

Year of fee payment: 20

Ref country code: GR

Payment date: 20090209

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20090218

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20090212

Year of fee payment: 20

Ref country code: DE

Payment date: 20090420

Year of fee payment: 20

Ref country code: IT

Payment date: 20090225

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20090217

Year of fee payment: 20

Ref country code: CH

Payment date: 20090505

Year of fee payment: 20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20100202

BE20 Be: patent expired

Owner name: *BAYER CORP.

Effective date: 20100203

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20100202

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20100204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100204

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20101104 AND 20101110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100203